Aerie completes enrollment of phase III trial for intraocular pressure eye drops

Aerie Pharmaceuticals (NSDQ:AERI) said today that it completed enrollment for its 2nd phase III registration trial, Mercury 2, evaluating its Roclatan once-daily eye drops for intraocular pressure resulting from glaucoma or ocular hypertension. The company’s Roclatan solution is a fixed dose combination of its drug Rhopressa (netarsudil ophthalmic solution) and latanoprost, a widely prescribed prostaglandin analogue. More than 690 patients are enrolled in the 3-arm study, comparing the Roclatan solution to each of its individual components. Get the full story at our sister site, Drug Delivery Business News. The post Aerie completes enrollment of phase III trial for intraocular pressure eye drops appeared first on MassDevice.
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Aerie Pharmaceuticals Source Type: news